Could we see an explosion of new anti-inflammatory therapies for heart disease?
Perhaps. That’s because Novartis may have just helped validate a long-standing theory: That targeting inflammation could play critical role in reducing the incidence of heart disease.
The pharma giant released top-line results from a 10,000-patient study indicating that its anti-inflammatory biologic drug, canakinumab, reduces cardiovascular risk in heart attack survivors. And after seeing several trials in this space flop over the years, the new study has cardiologists excited.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect